Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
HIV: A therapeutic advance for resource-limited settings

ANRS 12286 MOBIDIP, a clinical trial running in parallel in three countries in sub-Saharan Africa, shows that dual therapy with lamivudine and a boosted protease inhibitor is effective as second-line treatment in patients infected by HIV with multiple mutations. Such treatment deescalation will reduce costs, side effects, and the need for virological monitoring of patients. The results of this study are published in The Lancet HIV.

Published
31 May 2017
From
Eurekalert Inf Dis
Gilead and GSK go head-to-head with similar HIV drug data

Gilead Sciences Inc and GlaxoSmithKline Plc will go head-to-head with rival versions of an improved class of HIV medicines, after clinical studies showed the U.S. company's new drug bictegravir was as effective as GSK's product.

Published
31 May 2017
From
Reuters
Gilead’s Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for the Treatment of HIV-1 Meets Primary Endpoint in Four Phase 3 Studies

Gilead Sciences, Inc. (Nasdaq:GILD) today announced that four Phase 3 studies evaluating a fixed-dose combination of bictegravir (50mg) (BIC), a novel investigational integrase strand transfer inhibitor (INSTI), and emtricitabine/tenofovir alafenamide (200/25mg) (FTC/TAF) for the treatment of HIV-1 infection met their primary objectives of non-inferiority.

Published
30 May 2017
From
Gilead press release
New test detects latent HIV more accurately, moves closer to cure

Researchers at the University of Pittsburgh have come up with a more cost- and time-effective test that detects 'hidden' HIV more accurately.

Published
30 May 2017
From
HIV / AIDS News From Medical News Today
Agreements with cash incentives boost patient adherence to HIV therapy and rates of viral suppression

People who enter into a contract with their HIV healthcare provider to receive cash incentives in return for high levels of antiretroviral therapy (ART) adherence are more

Published
30 May 2017
By
Michael Carter
Taking Birth Control With HIV Treatment or PrEP Is Largely OK

Women taking various forms of hormonal contraceptives can likely combine them safely with antiretrovirals (ARVs), whether as HIV treatment or in the form of Truvada (tenofovir disoproxil fumarate/emtricitabine) as pre-exposure prophylaxis (PrEP) against the virus. The one ARV that may be problematic to combine with such forms of birth control is Sustiva (efavirenz), which is included in Atripla (efavirenz/tenofovir disoproxil fumarate/emtricitabine).

Published
30 May 2017
From
Poz
The Truth About HIV

Dr Chris van Tulleken explores the latest science around HIV, meeting health professionals, scientists, and individuals affected by it in the UK and South Africa.

Published
26 May 2017
From
BBC iPlayer (UK only, available until 24 June)
Life insurance policyholders with HIV urged to review life cover term

People with HIV who took out life insurance between 2009 and 2013 should review their policy, Unusual Risks has urged.

Published
24 May 2017
From
Professional Adviser
Unexpected side effects with generic abacavir – and potential for rare reactions to other generic ARVs

Several anecdotal reports of mouth ulcers have recently been reported in people switching to generic abacavir in the UK. This should highlight awareness of the potential of likely-rare new side effects, even when both formulations have been approved as bioequivalent.

Published
23 May 2017
From
HIV i-Base
Merck Receives CHMP Positive Opinion Recommending Approval of ISENTRESS® (raltegravir) 600 mg in the European Union

In adults and pediatric patients (weighing at least 40 kg), the recommended dosage is 1,200 mg (two 600 mg tablets) once daily for treatment-naïve patients or patients who are virologically suppressed on an initial regimen of ISENTRESS 400 mg twice daily.

Published
22 May 2017
From
Merck press release

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.